It’s 2021, and we are still in the throes of the COVID-19 pandemic. As more businesses reopen and some companies transition from remote to on-site workplaces, it’s natural for many people to feel concern about encountering the coronavirus at work. As such, COVID-19 safe practices for the workplace are probably here to stay, at least for the foreseeable future. Safe practices can incorporate COVID testing and can also impact a company’s existing drug and alcohol testing program, including how testing is conducted. Join us as we look into how employers can return employees to work in a safe manner and maintain a drug-free workplace by considering a telehealth collection option.
OraSure Technologies Susan Thompson – Senior Account Manager
Susan Thompson is a Senior Account Manager with OraSure Technologies’ Risk Assessment and Substance Abuse Testing division. She has over 25 years of experience in the drug testing industry and worked in several laboratories prior to coming to OraSure in 2003. Susan’s primary role at OraSure is to provide education, training, and program implementation for oral fluid drug testing. She works with industry partners, TPAs, laboratories, and corporate accounts in both the workplace drug testing and forensic toxicology markets.
Understanding the different COVID-19 testing options currently available
How vaccines will affect people coming back to work & what employers should be doing to keep their staff safe
How workplace drug and alcohol testing program fits into all of this
What is a telehealth collection & how does a typical telehealth collection work
Adding telehealth to your collection workflow
Telehealth collections and the future of drug testing
This webinar qualifies for One (1) hour of HR Certification Institute (HRCI) credits and One (1) Society for Human Resource Management (SHRM) Personal Development Credit (PDC) for participants who attend this webinar in its entirety.
Date: Thursday, August 5, 2021
Time: 10:00 am to 11:00 am PST (1:00 pm to 2:00 pm EST)